E

Emcure Pharmaceuticals Ltd
NSE:EMCURE

Watchlist Manager
Emcure Pharmaceuticals Ltd
NSE:EMCURE
Watchlist
Price: 1 314.15 INR 2.36% Market Closed
Market Cap: 248.5B INR
Have any thoughts about
Emcure Pharmaceuticals Ltd?
Write Note

Gross Margin
Emcure Pharmaceuticals Ltd

61%
Current
61%
Average
48.3%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
61%
=
Gross Profit
40.6B
/
Revenue
66.6B

Gross Margin Across Competitors

Country IN
Market Cap 248.5B INR
Gross Margin
61%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 710.5B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 3.3T DKK
Gross Margin
85%
Country US
Market Cap 373.5B USD
Gross Margin
69%
Country US
Market Cap 251.1B USD
Gross Margin
77%
Country CH
Market Cap 202.7B CHF
Gross Margin
73%
Country CH
Market Cap 183.3B CHF
Gross Margin
75%
Country UK
Market Cap 162.4B GBP
Gross Margin
82%
Country IE
Market Cap 146B USD
Gross Margin
68%
No Stocks Found

Emcure Pharmaceuticals Ltd
Glance View

Market Cap
248.5B INR
Industry
Pharmaceuticals

Emcure Pharmaceuticals Ltd is a IN-based company operating in Pharmaceuticals industry. The company is headquartered in Pune, Maharashtra and currently employs 11,146 full-time employees. The company went IPO on 2024-07-10. Emcure Pharmaceuticals Ltd is an India-based pharmaceutical company. The firm is engaged in developing, manufacturing and marketing a range of pharmaceutical products across several therapeutic areas. The company offers a range of products and services under formulations, biologics, and Active Pharmaceutical Ingredients (APIs). The company focuses on various key therapeutic areas, such as gynecology, cardiology, anti-infective, diabetes, biologics, mRNA vaccines, and vitamin, minerals and nutrients. The company offers products in both, chronic and acute segments. The firm's subsidiary, Gennova Biopharmaceuticals Limited, is a biotechnology company dedicated to developing, producing, and commercializing bio-therapeutics to address life-threatening diseases across various indications. The company has developed two platforms: Mammalian and Microbial. Its key APIs consists of S-Amlodipine, Dydrogesterone, Ferric Carboxymaltose, Ferrous Ascorbate, and Eribulin. The company operates approximately 13 manufacturing facilities.

EMCURE Intrinsic Value
1 371.66 INR
Undervaluation 4%
Intrinsic Value
Price
E

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
61%
=
Gross Profit
40.6B
/
Revenue
66.6B
What is the Gross Margin of Emcure Pharmaceuticals Ltd?

Based on Emcure Pharmaceuticals Ltd's most recent financial statements, the company has Gross Margin of 61%.